Rapport Therapeutics (NASDAQ:RAPP) Stock Price Down 5.6% – Should You Sell?

Rapport Therapeutics (NASDAQ:RAPP)’s share price was down 5.6% on Friday . The stock traded as low as $16.05 and last traded at $15.82. Approximately 11,780 shares were traded during mid-day trading, a decline of 88% from the average daily volume of 97,091 shares. The stock had previously closed at $16.75.

Rapport Therapeutics Price Performance

The firm’s 50 day simple moving average is $17.37 and its two-hundred day simple moving average is $20.34.

Rapport Therapeutics (NASDAQ:RAPP) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.07. On average, equities analysts anticipate that Rapport Therapeutics will post -3.65 EPS for the current fiscal year.

Institutional Trading of Rapport Therapeutics

Several large investors have recently modified their holdings of RAPP. Values First Advisors Inc. purchased a new position in Rapport Therapeutics during the third quarter valued at $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Rapport Therapeutics in the third quarter worth about $34,000. New York State Common Retirement Fund purchased a new stake in shares of Rapport Therapeutics in the fourth quarter worth about $62,000. JPMorgan Chase & Co. purchased a new stake in shares of Rapport Therapeutics in the third quarter worth about $83,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Rapport Therapeutics in the third quarter worth about $101,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.